이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IRRAS 관리

관리 기준 확인 2/4

IRRAS' CEO는 Will Martin, Jan2018 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 SEK 6.68M, 61.2% 로 구성됩니다. 61.2% 급여 및 38.8% 보너스(회사 주식 및 옵션 포함). 는 SEK 32.08K 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 32.08K. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 6.8 년입니다.

주요 정보

Will Martin

최고 경영자

SEK 6.7m

총 보상

CEO 급여 비율	61.2%
CEO 임기	5.8yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3.4yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Will Martin 의 보수는 IRRAS 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-SEK 196m
Mar 31 2023	n/a	n/a	-SEK 193m
Dec 31 2022	SEK 7m	SEK 4m	-SEK 167m
Sep 30 2022	n/a	n/a	-SEK 164m
Jun 30 2022	n/a	n/a	-SEK 141m
Mar 31 2022	n/a	n/a	-SEK 131m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 136m

보상 대 시장: Will 의 총 보상 ($USD 612.97K )은 Swedish 시장( $USD 257.75K ).

보상과 수익: 회사가 수익성이 없는 동안 Will 의 보상이 증가했습니다.

CEO

Will Martin (48 yo)

5.8yrs

테뉴어

SEK 6,679,000

보상

Mr. Will Martin has been the Chief Executive Officer at IRRAS AB (publ) since July 01, 2021. He had been the Chief Commercial Officer and a member of the executive management team of IRRAS AB (publ) (IRRAS...

리더십 팀

이름	위치	테뉴어	보상	소유권
Will Martin	President & CEO	5.8yrs	SEK 6.68m	0.018% SEK 32.1k
Kleanthis Xanthopoulos	Executive Director	2.3yrs	SEK 530.00k	1.15% SEK 2.1m
Griffen Stapp	Interim Chief Financial Officer	2.3yrs	데이터 없음	0.0022% SEK 4.0k
Sten Gustafsson	Director of Investor Relations	2.7yrs	데이터 없음	데이터 없음
Kellie Fontes	Vice President of Human Capital	5.8yrs	데이터 없음	0.083% SEK 151.0k
Niloufa Insanally	Head of Regulatory Affairs	4.2yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: IRRAS 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kleanthis Xanthopoulos	Executive Director	8.8yrs	SEK 530.00k	1.15% SEK 2.1m
Marios Fotiadis	Chairman of the Board	11.8yrs	SEK 540.00k	20.2% SEK 36.7m
Anita Tollstadius	Independent Director	6.8yrs	SEK 380.00k	0.010% SEK 18.4k
Christos Panotopoulos	Special Advisor & Member of Clinical Advisory Board	5.4yrs	데이터 없음	데이터 없음
Catherine Gilmore-Lawless	Independent Director	4.5yrs	SEK 471.00k	데이터 없음

6.8yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: IRRAS 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

IRRAS 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Insufficient new directors

Insufficient new directors

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원